Abbott and Medtronic DES double hit likely to increase impact on competitors
This article was originally published in Clinica
Abbott's Xience and Medtronic's Endeavor are highly likely to reach the US market at the same time - during the first quarter of 2008 - causing a bigger than expected impact on competing firms, say analysts. The double approval will mean that rivals Boston Scientific and J&J will not have time "to establish a foothold against newer entrants", said Morgan Stanley analyst Glenn Reicin. The prediction comes after Mr Reicin reported that the FDA has approved the manufacturing facility where Xience is to be produced. If the Xience DES is approved by the end of the first quarter, it could add $150m to Abbott's 2008 sales, said the analyst.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.